Bolt Biotherapeutics to acquire Prana Therapies in reverse merger, secured $120M financing

Bolt Biotherapeutics announced a stock‑for‑stock reverse merger with Prana Therapies. The transaction is supported by a $120 million financing package.

The deal will bring Prana’s lead antibody into Bolt’s pipeline, with plans to run multiple Phase 2 trials targeting inflammatory diseases.

Both companies expect the combined resources to accelerate development and broaden their presence in the inflammation market.